Lack of Coverage Decisions, Contracts Leaves Foundation Medicine With Thousands of Unpaid Tests

Nov 25, 2015

NEW YORK (GenomeWeb) – As Foundation Medicine seeks to grow revenues from its clinical cancer profiling tests, the company has been hampered by a lack of coverage decisions from Medicare and no contracts with most commercial payors, resulting in payment delays and tens of thousands of unpaid tests.

The firm provides two clinical tests for cancer patients, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, each assaying several hundred genes for mutations that may impact treatment decisions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Featured White Papers

Detect low-level somatic mutations in FFPE samples using an extended RAS research assay

InnoStamp 40 and InnoScan 1100AL: a complete automated platform for microstructured cell arrays

Albumin Removal Reference Applications

Apr

26

Featured Webinar

Evaluation of a Pan-Cancer Cell-Free Assay to Meet Unmet Research Needs

In this webinar, the second in the “New Frontiers in Liquid Biopsy Research” series, Luca Quagliata, Senior Consultant in the Molecular Pathology Unit at University Hospital Basel, will share two specific unmet needs within his lab’s liquid biopsy research that led to the eventual evaluation, adoption, and implementation of the latest liquid biopsy Oncomine NGS solutions from Thermo Fisher.

May

01

Featured Webinar

Analytical Validation of a Liquid Biopsy Assay for High-Sensitivity Molecular Profiling

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May

08

Featured Webinar

Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

May

22

Featured Webinar

From Qualitative to Quantitative: Experiences with a cfDNA Assay in Metastatic Breast Cancer Research

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.

Main menu